BioSpace News Archive

PureTech Health plc announces its half-yearly results for the six months ended June 30, 2021.

Vertex Pharmaceuticals Incorporated and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.

Dante Labs announced today the appointment of Mark Van Oene as a member of its Board of Directors.

ITOCO INC. (OTC PINK:ITMC) is pleased to announce that Mr. Erik Gordillo Enamorado has joined ITOCO as Project Coordinator Carbon Credits and Chief Agricultural Liaison.

Stealth BioTherapeutics Corp today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Adminstration (FDA) for elamipretide, the company’s lead product candidate, for the treatment of Barth syndrome, an ultra-rare genetic condition with no FDA- or EMA-approved therapies.

Sight Sciences, Inc., a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world’s most prevalent eye diseases, announced publication in Clinical Ophthalhmology of favorable 24-month outcomes from a single center open-label study of the OMNI® Surgical System conducted in Germany.

Q BioMed Inc. is expected to receive a patent in Korea, adding to the already issued patents in Canada and Japan .

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose

Stryker has announced the launch of its T2 Alpha Femur Retrograde Nailing System.

PolarityTE, Inc. today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE ® with a proposed indication for chronic cutaneous ulcers, which was filed on July 23, 2021.